Published in Clin Microbiol Rev on April 01, 2005
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
The role of toxin A and toxin B in Clostridium difficile infection. Nature (2010) 5.32
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol (2008) 3.37
Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol (2010) 2.61
The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes (2011) 2.37
Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog (2009) 2.29
Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med (2012) 2.20
Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun (2006) 2.09
Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol (2009) 1.97
Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol (2008) 1.89
Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev (2013) 1.85
Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol (2010) 1.82
Cloning and variation of ground state intestinal stem cells. Nature (2015) 1.78
Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology (2014) 1.77
Morphological and genetic diversity of temperate phages in Clostridium difficile. Appl Environ Microbiol (2007) 1.71
Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection. Cell Host Microbe (2015) 1.66
Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis. Gastroenterology (2007) 1.60
Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol (2008) 1.53
Clostridium difficile has two parallel and essential Sec secretion systems. J Biol Chem (2011) 1.50
Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature (2016) 1.47
Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol (2012) 1.47
Motility and flagellar glycosylation in Clostridium difficile. J Bacteriol (2009) 1.45
Structural organization of the functional domains of Clostridium difficile toxins A and B. Proc Natl Acad Sci U S A (2010) 1.44
Culture-independent analysis of indomethacin-induced alterations in the rat gastrointestinal microbiota. Appl Environ Microbiol (2006) 1.42
Importance of Glutamate Dehydrogenase (GDH) in Clostridium difficile Colonization In Vivo. PLoS One (2016) 1.40
Contact with enterocyte-like Caco-2 cells induces rapid upregulation of toxin production by Clostridium perfringens type C isolates. Cell Microbiol (2009) 1.38
The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes (2010) 1.37
Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc Natl Acad Sci U S A (2006) 1.35
SleC is essential for germination of Clostridium difficile spores in nutrient-rich medium supplemented with the bile salt taurocholate. J Bacteriol (2009) 1.35
Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc Natl Acad Sci U S A (2005) 1.35
A novel genetic switch controls phase variable expression of CwpV, a Clostridium difficile cell wall protein. Mol Microbiol (2009) 1.30
Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes (2011) 1.29
Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol (2008) 1.28
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun (2011) 1.24
Microarray identification of Clostridium difficile core components and divergent regions associated with host origin. J Bacteriol (2009) 1.24
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22
Clostridium difficile toxins: mediators of inflammation. J Innate Immun (2012) 1.21
Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21
Clostridium difficile infection. Am J Med Sci (2010) 1.17
Implantation of the human embryo requires Rac1-dependent endometrial stromal cell migration. Proc Natl Acad Sci U S A (2008) 1.17
Clostridium difficile has an original peptidoglycan structure with a high level of N-acetylglucosamine deacetylation and mainly 3-3 cross-links. J Biol Chem (2011) 1.17
Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16
The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A. PLoS One (2011) 1.13
Autoproteolytic cleavage mediates cytotoxicity of Clostridium difficile toxin A. Naunyn Schmiedebergs Arch Pharmacol (2010) 1.12
The Clostridium difficile cell wall protein CwpV is antigenically variable between strains, but exhibits conserved aggregation-promoting function. PLoS Pathog (2011) 1.11
C3 exoenzymes, novel insights into structure and action of Rho-ADP-ribosylating toxins. Naunyn Schmiedebergs Arch Pharmacol (2006) 1.11
Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. J Bacteriol (2011) 1.10
Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A. BMC Infect Dis (2009) 1.10
Clostridium difficile and the microbiota. J Clin Invest (2014) 1.09
Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis (2012) 1.09
Mutagenic analysis of the Clostridium difficile flagellar proteins, FliC and FliD, and their contribution to virulence in hamsters. Infect Immun (2011) 1.09
Genetic manipulation of Clostridium difficile. Curr Protoc Microbiol (2011) 1.08
PrsW is required for colonization, resistance to antimicrobial peptides, and expression of extracytoplasmic function σ factors in Clostridium difficile. Infect Immun (2011) 1.08
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine (2009) 1.08
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Difference in the cytotoxic effects of toxin B from Clostridium difficile strain VPI 10463 and toxin B from variant Clostridium difficile strain 1470. Infect Immun (2006) 1.07
Application of mutated Clostridium difficile toxin A for determination of glucosyltransferase-dependent effects. Infect Immun (2006) 1.06
Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun (2007) 1.06
Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes (2011) 1.06
Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury. Gastroenterology (2010) 1.04
Comparison of real-time PCR techniques to cytotoxigenic culture methods for diagnosing Clostridium difficile infection. J Clin Microbiol (2010) 1.03
TcdC does not significantly repress toxin expression in Clostridium difficile 630ΔErm. PLoS One (2012) 1.02
Clostridium difficile toxin B-induced necrosis is mediated by the host epithelial cell NADPH oxidase complex. Proc Natl Acad Sci U S A (2013) 1.02
Clostridium difficile in the ICU: the struggle continues. Chest (2011) 1.01
Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol (2016) 1.01
Rapid stool-based diagnosis of Clostridium difficile infection by real-time PCR in a children's hospital. J Clin Microbiol (2011) 1.01
Structural basis for substrate recognition in the enzymatic component of ADP-ribosyltransferase toxin CDTa from Clostridium difficile. J Biol Chem (2009) 1.00
Evidence that Clostridium difficile TcdC is a membrane-associated protein. J Bacteriol (2006) 1.00
The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol (2013) 1.00
Spo0A differentially regulates toxin production in evolutionarily diverse strains of Clostridium difficile. PLoS One (2013) 0.99
Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog (2009) 0.99
Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins. Nat Struct Mol Biol (2011) 0.99
Transcriptional profiling of Clostridium difficile and Caco-2 cells during infection. J Infect Dis (2010) 0.99
Whole genome sequencing reveals potential spread of Clostridium difficile between humans and farm animals in the Netherlands, 2002 to 2011. Euro Surveill (2014) 0.99
Prevalence and diversity of toxigenic Clostridium perfringens and Clostridium difficile among swine herds in the midwest. Appl Environ Microbiol (2010) 0.98
Spore formation and toxin production in Clostridium difficile biofilms. PLoS One (2014) 0.98
Novel one-step method for detection and isolation of active-toxin-producing Clostridium difficile strains directly from stool samples. J Clin Microbiol (2011) 0.98
Quantitative proteomic analysis of type III secretome of enteropathogenic Escherichia coli reveals an expanded effector repertoire for attaching/effacing bacterial pathogens. Mol Cell Proteomics (2012) 0.98
KEGG orthology-based annotation of the predicted proteome of Acropora digitifera: ZoophyteBase - an open access and searchable database of a coral genome. BMC Genomics (2013) 0.98
Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol (2010) 0.97
Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother (2008) 0.97
Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for Clostridium difficile toxin B. Cell Res (2014) 0.97
Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity. Proc Natl Acad Sci U S A (2015) 0.97
Murine Chlamydia trachomatis genital infection is unaltered by depletion of CD4+ T cells and diminished adaptive immunity. J Infect Dis (2011) 0.96
Cholesterol- and sphingolipid-rich microdomains are essential for microtubule-based membrane protrusions induced by Clostridium difficile transferase (CDT). J Biol Chem (2011) 0.96
Vibrio parahaemolyticus inhibition of Rho family GTPase activation requires a functional chromosome I type III secretion system. Infect Immun (2008) 0.96
Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic strains: an epidemiological model. Sci Rep (2015) 0.96
Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease. Eur J Clin Microbiol Infect Dis (2010) 0.96
TcsL is an essential virulence factor in Clostridium sordellii ATCC 9714. Infect Immun (2011) 0.95
Medical microbiology: A toxin contest. Nature (2010) 0.95
Immune responses to Clostridium difficile infection. Trends Mol Med (2012) 0.95
Diversity and Evolution in the Genome of Clostridium difficile. Clin Microbiol Rev (2015) 0.94
Nationwide surveillance study of Clostridium difficile in Australian neonatal pigs shows high prevalence and heterogeneity of PCR ribotypes. Appl Environ Microbiol (2014) 0.94
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun (2014) 0.94
Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile. J Bacteriol (2012) 0.93
Impenetrable barriers or entry portals? The role of cell-cell adhesion during infection. J Cell Biol (2011) 0.93
Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am (2009) 0.93
A segment of 97 amino acids within the translocation domain of Clostridium difficile toxin B is essential for toxicity. PLoS One (2013) 0.93
Interactions Between the Gastrointestinal Microbiome and Clostridium difficile. Annu Rev Microbiol (2015) 0.93
The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell (1992) 30.02
Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell (1995) 24.99
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis (2001) 6.92
Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature (1995) 6.08
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91
Aetiology of antimicrobial-agent-associated colitis. Lancet (1978) 5.91
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
The cellular functions of small GTP-binding proteins. Science (1990) 5.16
The small GTP-binding protein Rho regulates a phosphatidylinositol 4-phosphate 5-kinase in mammalian cells. Cell (1994) 4.80
A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol (1998) 4.79
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet (2001) 4.59
Clostridium difficile--associated diarrhea. Clin Infect Dis (1998) 4.06
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Role of citron kinase as a target of the small GTPase Rho in cytokinesis. Nature (1998) 3.55
Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett (2000) 3.50
Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase. J Biol Chem (1989) 3.47
Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol (1998) 3.34
Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet (1998) 3.29
Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI. Cell (2000) 3.22
Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest (1988) 3.12
Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun (1988) 3.11
The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem (1995) 3.02
Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins. Oncogene (1990) 2.89
Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin. J Clin Microbiol (1979) 2.86
Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med (2001) 2.72
Rho protein regulates tight junctions and perijunctional actin organization in polarized epithelia. Proc Natl Acad Sci U S A (1995) 2.70
A family of clostridial and streptococcal ligand-binding proteins with conserved C-terminal repeat sequences. Mol Microbiol (1991) 2.62
Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology (1980) 2.60
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol (2000) 2.50
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect Immun (1997) 2.42
Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins. Infect Immun (1978) 2.39
MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO J (1997) 2.38
Regulated transcription of Clostridium difficile toxin genes. Mol Microbiol (1998) 2.28
Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem (1997) 2.25
Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest (1994) 2.25
Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol (2003) 2.24
CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci U S A (1994) 2.22
A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21. Proc Natl Acad Sci U S A (1991) 2.22
Post-translational modifications of p21rho proteins. J Biol Chem (1992) 2.17
Identification of distinct cytoplasmic targets for ras/R-ras and rho regulatory proteins. J Biol Chem (1989) 2.15
Clostridium difficile toxin B acts on the GTP-binding protein Rho. J Biol Chem (1994) 2.09
A common motif of eukaryotic glycosyltransferases is essential for the enzyme activity of large clostridial cytotoxins. J Biol Chem (1998) 2.08
Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.07
Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun (1987) 2.06
Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology (2001) 2.04
An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. Can Commun Dis Rep (1999) 2.04
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol Gen Genet (1992) 2.00
Protein prenylation: a mediator of protein-protein interactions. Science (1993) 1.95
Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile. J Clin Microbiol (2000) 1.91
Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology (2003) 1.91
The toxigenic element of Clostridium difficile strain VPI 10463. Microb Pathog (1995) 1.89
Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci U S A (2001) 1.89
Differential effects of Clostridium difficile toxins on tissue-cultured cells. J Clin Microbiol (1982) 1.87
Crystal structure of human RhoA in a dominantly active form complexed with a GTP analogue. J Biol Chem (1998) 1.86
Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun (2001) 1.85
Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the N-terminal part of the holotoxin. J Biol Chem (1997) 1.83
Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Microbiol (2002) 1.83
Closing in on the toxic domain through analysis of a variant Clostridium difficile cytotoxin B. Mol Microbiol (1995) 1.81
Prevalence of toxin A negative/B positive Clostridium difficile strains. J Hosp Infect (1999) 1.80
pH-induced conformational changes in Clostridium difficile toxin B. Infect Immun (2000) 1.75
Studies of UV-inducible promoters from Clostridium perfringens in vivo and in vitro. Mol Microbiol (1988) 1.72
Purification and characterization of Clostridium sordellii lethal toxin and cross-reactivity with Clostridium difficile cytotoxin. Infect Immun (1987) 1.72
Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain. Eur J Clin Microbiol Infect Dis (2001) 1.71
Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci U S A (1997) 1.70
Interaction of cytopathogenic toxin from Clostridium difficile with cells in tissue culture. Scand J Infect Dis Suppl (1980) 1.68
p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest (2000) 1.68
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65
Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother (2003) 1.64
Purification and characterisation of toxin B from a strain of Clostridium difficile that does not produce toxin A. J Med Microbiol (1991) 1.63
Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology (1992) 1.62
New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol (2003) 1.61
Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids. Microbiology (1999) 1.61
Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun (2000) 1.60
A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins. J Biol Chem (1999) 1.58
Both stimulatory and inhibitory GDP/GTP exchange proteins, smg GDS and rho GDI, are active on multiple small GTP-binding proteins. Biochem Biophys Res Commun (1992) 1.55
Characterization of the enzymatic component of the ADP-ribosyltransferase toxin CDTa from Clostridium difficile. Infect Immun (2001) 1.54
Environmental response and autoregulation of Clostridium difficile TxeR, a sigma factor for toxin gene expression. J Bacteriol (2002) 1.53
Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol (2004) 1.52
Infection of hamsters with epidemiologically important strains of Clostridium difficile. J Infect Dis (2001) 1.52
The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. J Clin Invest (1995) 1.51
Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal alpha 1-3Gal beta 1-4GlcNAc sequences. Arch Biochem Biophys (1987) 1.51
The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med (2002) 1.50
Genetic rearrangements in the pathogenicity locus of Clostridium difficile strain 8864--implications for transcription, expression and enzymatic activity of toxins A and B. Mol Gen Genet (1998) 1.49
Low pH-induced formation of ion channels by clostridium difficile toxin B in target cells. J Biol Chem (2001) 1.49
Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblasts. Exp Cell Res (1983) 1.46
Cellular uptake of Clostridium difficile toxin B. Translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells. J Biol Chem (2003) 1.45
Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun (1991) 1.44
Faecal toxin and severity of antibiotic-associated pseudomembranous colitis. J Clin Pathol (1981) 1.43
Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol (2003) 1.43
Crystal structure of RhoA-GDP and its functional implications. Nat Struct Biol (1997) 1.42
Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest (1988) 1.41
Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun (1988) 1.40
Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. J Clin Invest (1997) 1.39
Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis. Proc Natl Acad Sci U S A (2003) 1.59
Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc Natl Acad Sci U S A (2006) 1.35
Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog (2010) 1.26
Bacillus anthracis oedema toxin as a cause of tissue necrosis and cell type-specific cytotoxicity. Cell Microbiol (2005) 1.25
Clostridium difficile toxin B activates dual caspase-dependent and caspase-independent apoptosis in intoxicated cells. Cell Microbiol (2002) 1.25
Clostridium difficile infection. Am J Med Sci (2010) 1.17
A method adapting microarray technology for signature-tagged mutagenesis of Desulfovibrio desulfuricans G20 and Shewanella oneidensis MR-1 in anaerobic sediment survival experiments. Appl Environ Microbiol (2005) 1.12
Effects of endogenous D-alanine synthesis and autoinhibition of Bacillus anthracis germination on in vitro and in vivo infections. Infect Immun (2007) 1.11
Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog (2013) 1.08
Inhibition of Bacillus anthracis spore outgrowth by nisin. Antimicrob Agents Chemother (2008) 1.08
Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy. PLoS Pathog (2009) 1.02
Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect Immun (2008) 1.01
Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J Infect Dis (2010) 1.01
Toxin-induced resistance in Bacillus anthracis lethal toxin-treated macrophages. Proc Natl Acad Sci U S A (2003) 1.00
CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies. Infect Immun (2010) 1.00
Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1. Cell Microbiol (2006) 0.99
The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes. Infect Immun (2009) 0.99
Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity. Vaccine (2011) 0.99
Variations in virulence and molecular biology among emerging strains of Clostridium difficile. Microbiol Mol Biol Rev (2013) 0.99
Inflammatory cytokine response to Bacillus anthracis peptidoglycan requires phagocytosis and lysosomal trafficking. Infect Immun (2010) 0.99
Variations in lethal toxin and cholesterol-dependent cytolysin production correspond to differences in cytotoxicity among strains of Clostridium sordellii. FEMS Microbiol Lett (2006) 0.98
Clostridium sordellii toxic shock syndrome. Lancet Infect Dis (2009) 0.96
Desulfovibrio sp. genes involved in the respiration of sulfate during metabolism of hydrogen and lactate. Appl Environ Microbiol (2002) 0.96
Medical microbiology: A toxin contest. Nature (2010) 0.95
Regulatory interactions of a virulence-associated serine/threonine phosphatase-kinase pair in Bacillus anthracis. J Bacteriol (2009) 0.95
TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing. Mol Microbiol (2012) 0.93
Functional comparison of the two Bacillus anthracis glutamate racemases. J Bacteriol (2007) 0.92
Decreased glycogen synthase kinase 3-beta levels and related physiological changes in Bacillus anthracis lethal toxin-treated macrophages. Cell Microbiol (2003) 0.92
Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ. PLoS One (2011) 0.91
Glycogen synthase kinase 3 activation is important for anthrax edema toxin-induced dendritic cell maturation and anthrax toxin receptor 2 expression in macrophages. Infect Immun (2011) 0.90
Resistance of human alveolar macrophages to Bacillus anthracis lethal toxin. J Immunol (2009) 0.90
Increased cAMP in monocytes augments Notch signaling mechanisms by elevating RBP-J and transducin-like enhancer of Split (TLE). J Biol Chem (2013) 0.89
High-throughput, single-cell analysis of macrophage interactions with fluorescently labeled Bacillus anthracis spores. Appl Environ Microbiol (2008) 0.87
Genes that enhance the ecological fitness of Shewanella oneidensis MR-1 in sediments reveal the value of antibiotic resistance. Appl Environ Microbiol (2006) 0.87
Mutational analysis of the enzymatic domain of Clostridium difficile toxin B reveals novel inhibitors of the wild-type toxin. Infect Immun (2003) 0.86
Identification of genes that confer sediment fitness to Desulfovibrio desulfuricans G20. Appl Environ Microbiol (2007) 0.85
Bacillus anthracis edema toxin activates nuclear glycogen synthase kinase 3beta. Infect Immun (2008) 0.85
The mechanism of Bacillus anthracis intracellular germination requires multiple and highly diverse genetic loci. Infect Immun (2008) 0.83
Clostridium sordellii lethal toxin is maintained in a multimeric protein complex. Infect Immun (2004) 0.82
Evidence for chimeric sequences formed during random arbitrarily primed PCR. J Microbiol Methods (2003) 0.80
Elucidating the in vivo targets of bacterial toxins. Future Microbiol (2007) 0.79
Adenomatous polyposis coli protein associates with C/EBP beta and increases Bacillus anthracis edema toxin-stimulated gene expression in macrophages. J Biol Chem (2011) 0.79
Toxin inhibition of antimicrobial factors induced by Bacillus anthracis peptidoglycan in human blood. Infect Immun (2013) 0.78
Differential expression of Desulfovibrio vulgaris genes in response to Cu(II) and Hg(II) toxicity. Appl Environ Microbiol (2004) 0.78
Autoregulatory characteristics of a Bacillus anthracis serine/threonine kinase. J Bacteriol (2011) 0.77
Critical intermediate steps in Clostridium sordellii lethal toxin-induced apoptosis. Biochem Biophys Res Commun (2007) 0.76
Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2012) 0.75
Serum amyloid A protects murine macrophages from lethal toxin-mediated death. Cell Immunol (2011) 0.75
Differential inflammatory responses triggered by toxic small molecules. Environ Sci Pollut Res Int (2011) 0.75